ADP 31415

Drug Profile

ADP 31415

Alternative Names: ADP31415

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Almirall S.A.
  • Class Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pemphigus vulgaris

Most Recent Events

  • 07 Nov 2016 Phase-I clinical trials in Pemphigus vulgaris in Spain
  • 24 Jul 2015 Preclinical trials in Pemphigus vulgaris in Spain (unspecified route) (Almirall's pipeline, July 2015)
  • 26 Jan 2015 ADP 31415 - Almirall receives Orphan Drug status for Pemphigus vulgaris in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top